RT Journal Article SR Electronic T1 Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study) JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.08.25.22279158 DO 10.1101/2022.08.25.22279158 A1 Nancy H. L. Leung A1 Samuel M. S. Cheng A1 Carolyn A. Cohen A1 Mario Martín-Sánchez A1 Niki Y. M. Au A1 Leo L. H. Luk A1 Leo C. H. Tsang A1 Kelvin K. H. Kwan A1 Sara Chaothai A1 Lison W. C. Fung A1 Alan W. L. Cheung A1 Karl C. K. Chan A1 John K. C. Li A1 Yvonne Y. Ng A1 Prathanporn Kaewpreedee A1 Janice Z. Jia A1 Dennis K. M. Ip A1 Leo L. M. Poon A1 Gabriel M. Leung A1 J. S. Malik Peiris A1 Sophie A. Valkenburg A1 Benjamin J. Cowling YR 2022 UL http://medrxiv.org/content/early/2022/08/26/2022.08.25.22279158.abstract AB Background There are few trials comparing homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines and mRNA vaccines.Methods We conducted an open-label randomized trial in adults >=18 years of age who received two doses of inactivated vaccine (CoronaVac) or mRNA vaccine (BNT162b2) >=6 months earlier, randomised in 1:1 ratio to receive a third dose of either vaccine. We compared the reactogenicity, immunogenicity and cell-mediated immune responses, and assessed vaccine efficacy against infections during follow-up.Results We enrolled 219 adults who previously received two doses of CoronaVac and randomised to CoronaVac (“CC-C”, n=101) or BNT162b2 (“CC-B”, n=118) third dose; and 232 adults who previously received BNT162b2 and randomised to CoronaVac (“BB-C”, n=118) or BNT162b2 (“BB-B”, n=114). There were more frequent reports of mild reactions in recipients of third-dose BNT162b2, which generally subsided within 7 days. Third doses significantly increased neutralising PRNT50 antibody titers against ancestral virus and Omicron BA.1 variant in all four study arms, and against Omicron BA.2 in all arms except CC-C, with statistically significant improvements for recipients of a third dose of BNT162b2 over CoronaVac irrespective of prior vaccine type. Boosting of CD4+ T cells only occurred in CoronaVac-primed arms, but we did not identify overall differences between vaccine groups in CD4+ and CD8+ T cell responses. When Omicron BA.2 was circulating, we identified 58 infections with cumulative incidence of 15.3% and 15.4% in the CC-C and CC-B (p=0.93), and 16.7% and 14.0% in the BB-C and BB-B arms, respectively (p=0.56).Conclusions Similar levels of incidence of infection in each arm suggest all third dose combinations may provide similar degrees of protection against prevalent Omicron BA.2 infection, despite very weak antibody responses to BA.2 in the recipients of a CoronaVac third dose. Further research is warranted to identify appropriate correlates of protection for inactivated COVID-19 vaccines.Competing Interest StatementBJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no other potential conflicts of interest.Clinical TrialClinicaltrials.gov NCT05057169Funding StatementThis project was supported by the Health and Medical Research Fund (grant no. COVID19F09), and the Theme-based Research Scheme of the Research Grants Council of the Hong Kong Special Administrative Region, China (grant no. T11-705/21-N). BJC is supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. 75N93021C00015, and a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol (Clinicaltrials.gov NCT05057169) was approved by the Institutional Review Board of the University of Hong Kong (ref: UW 21-492).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData to reproduce the results shown here will be posted on github after peer review and publication of our article.